Flagship Pioneering: Difference between revisions
Content deleted Content added
Timtempleton (talk | contribs) →History: added context |
add industry |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 6: | Line 6: | ||
| type = [[Private company|Private]] |
| type = [[Private company|Private]] |
||
| foundation = {{start date and age|1999}} |
| foundation = {{start date and age|1999}} |
||
| key_people = {{ubl|[[Noubar Afeyan]] {{small|(Founder & [[Chief executive officer|CEO]])}}}} |
| key_people = {{ubl|[[Noubar Afeyan]] {{small|(Co-Founder & [[Chief executive officer|CEO]])}}}} |
||
| location_city = [[Cambridge, Massachusetts]] |
| location_city = [[Cambridge, Massachusetts]] |
||
| location_country = United States |
| location_country = United States |
||
| locations = |
| locations = |
||
| industry = |
| industry = [[Biotechnology]], [[Venture capital]] |
||
| homepage = {{url|https://www.flagshippioneering.com/}} |
| homepage = {{url|https://www.flagshippioneering.com/}} |
||
}} |
}} |
||
| Line 16: | Line 16: | ||
== History == |
== History == |
||
The company was founded in Cambridge in 1999 by [[Noubar Afeyan]] under the name NewcoGen (short for "new company generation"), but later changed its name to Flagship Ventures, and again in 2016 to Flagship Pioneering.<ref name="bbj1" /> |
The company was founded in Cambridge in 1999 by [[Noubar Afeyan]] and Ed Kania under the name NewcoGen (short for "new company generation"), but later changed its name to Flagship Ventures, and again in 2016 to Flagship Pioneering.<ref name="bbj1" /> |
||
In late 2010, Flagship formed [[Moderna]], which focuses on [[drug discovery]], [[drug development]], and [[vaccine]] technologies based exclusively on [[messenger RNA]] (mRNA) technology.<ref name="businessinsider" /><ref>{{cite news |last=Garde |first=Damian |date=November 10, 2020 |title=The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race |url=https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/ |work=Stat }}</ref> |
In late 2010, Flagship formed [[Moderna]], which focuses on [[drug discovery]], [[drug development]], and [[vaccine]] technologies based exclusively on [[messenger RNA]] (mRNA) technology, and which is famous for its [[Moderna COVID-19 vaccine|COVID-19 vaccine]].<ref name="businessinsider" /><ref>{{cite news |last=Garde |first=Damian |date=November 10, 2020 |title=The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race |url=https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/ |work=Stat }}</ref> |
||
In 2013, Flagship helped fund the creation of [[Editas Medicine]] to use [[CRISPR gene editing]] for the development of [[medication|pharmacological therapies]], originally based on the genetic engineering protein [[Cas9]]. Editas was founded by [[Feng Zhang]], [[Jennifer Doudna]], [[George Church (geneticist)|George Church]], [[J. Keith Joung]], and [[David R. Liu]]. Doudna would later win the [[Nobel Prize in Chemistry]] in 2020 for her work on CRISPR, but quit Editas in 2014 over legal differences over intellectual property.<ref>{{Cite book|last=Isaacson|first=Walter|title=[[The Code Breaker]]|publisher=[[Simon & Schuster]]|year=2021|isbn=978-1-9821-1585-2|pages= |
In 2013, Flagship helped fund the creation of [[Editas Medicine]] to use [[CRISPR gene editing]] for the development of [[medication|pharmacological therapies]], originally based on the genetic engineering protein [[Cas9]]. Editas was founded by [[Feng Zhang]], [[Jennifer Doudna]], [[George Church (geneticist)|George Church]], [[J. Keith Joung]], and [[David R. Liu]]. Doudna would later win the [[Nobel Prize in Chemistry]] in 2020 for her work on CRISPR, but quit Editas in 2014 over legal differences over intellectual property.<ref>{{Cite book|last=Isaacson|first=Walter|title=[[The Code Breaker]]|publisher=[[Simon & Schuster]]|year=2021|isbn=978-1-9821-1585-2|pages=208–213|author-link=Walter Isaacson}}</ref> |
||
==See also== |
==See also== |
||
Latest revision as of 18:42, 4 March 2024
| Company type | Private |
|---|---|
| Industry | Biotechnology, Venture capital |
| Founded | 1999 |
| Headquarters | , United States |
Key people |
|
| Website | www |
Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts[1][2][3] that invests in biotechnology, life sciences, health and sustainability companies.[4] Portfolio companies include Moderna,[5] Indigo Agriculture, Inari Agriculture and Novomer.[6] The firm both funds and incubates companies.[7]
History[edit]
The company was founded in Cambridge in 1999 by Noubar Afeyan and Ed Kania under the name NewcoGen (short for "new company generation"), but later changed its name to Flagship Ventures, and again in 2016 to Flagship Pioneering.[2]
In late 2010, Flagship formed Moderna, which focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA (mRNA) technology, and which is famous for its COVID-19 vaccine.[5][8]
In 2013, Flagship helped fund the creation of Editas Medicine to use CRISPR gene editing for the development of pharmacological therapies, originally based on the genetic engineering protein Cas9. Editas was founded by Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David R. Liu. Doudna would later win the Nobel Prize in Chemistry in 2020 for her work on CRISPR, but quit Editas in 2014 over legal differences over intellectual property.[9]
See also[edit]
References[edit]
- ^ Fry, Erika (May 19, 2020). "How the biotech investor behind Moderna is using the 'immigrant mindset' to take on COVID-19". Fortune.
- ^ a b Stendahl, Max (December 15, 2016). "A new name and new fund will ensure Cambridge's Flagship 'feels like a startup'". Boston Business Journal.
- ^ Saltzman, Jonathan (April 2, 2020). "VC firm Flagship Pioneering raises $1.1b for biotech startups, despite reeling economy". Boston Globe.
- ^ National Research Council, Division on Earth and Life Studies, Board on Chemical Sciences and Technology, Committee on Challenges in Chemistry Graduate Education (2012). Challenges in Chemistry Graduate Education: A Workshop Summary. National Academies Press. p. 42. ISBN 978-0-309-25708-4.
{{cite book}}: CS1 maint: multiple names: authors list (link) - ^ a b Dunn, Andrew (May 23, 2020). "The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time". Business Insider.
- ^ "Companies". Flagship Pioneering. Retrieved 2021-04-21.
- ^ DeAngelis, Allison (April 2, 2020). "With $1.1B in hand, life sciences investor Flagship rewrites its rulebook". Boston Business Journal.
- ^ Garde, Damian (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat.
- ^ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 208–213. ISBN 978-1-9821-1585-2.
External links[edit]
- At Flagship Pioneering, the brazen venture capital firm that bankrolled Moderna, there’s a tolerance for failure but not for weakness (Stat, February 2021)
  | This article about a private equity or venture capital firm based in the United States is a stub. You can help Wikipedia by expanding it. |